Cocrystal Pharma Files 8-K
Ticker: COCP · Form: 8-K · Filed: Oct 31, 2024 · CIK: 1412486
| Field | Detail |
|---|---|
| Company | Cocrystal Pharma, INC. (COCP) |
| Form Type | 8-K |
| Filed Date | Oct 31, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, SEC filing, reporting
TL;DR
Cocrystal Pharma filed a standard 8-K, no major news.
AI Summary
Cocrystal Pharma, Inc. filed an 8-K on October 31, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This 8-K filing indicates routine corporate reporting by Cocrystal Pharma, Inc. to the SEC, without disclosing new material events or financial performance.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report and does not contain any new material information that would significantly impact the company's risk profile.
Key Players & Entities
- Cocrystal Pharma, Inc. (company) — Registrant
- October 31, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 19805 N. Creek Parkway (address) — Principal executive offices
- Bothell, WA (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to provide Financial Statements and Exhibits as of October 31, 2024.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported in this filing is October 31, 2024.
In which state is Cocrystal Pharma, Inc. incorporated?
Cocrystal Pharma, Inc. is incorporated in Delaware.
What is the address of Cocrystal Pharma, Inc.'s principal executive offices?
The address of Cocrystal Pharma, Inc.'s principal executive offices is 19805 N. Creek Parkway, Bothell, WA 98011.
Does this filing disclose any specific new material events or financial results?
Based on the provided text, this filing appears to be a routine report and does not explicitly disclose any specific new material events or detailed financial results beyond the standard reporting categories.
Filing Stats: 430 words · 2 min read · ~1 pages · Grade level 10.6 · Accepted 2024-10-31 09:10:00
Filing Documents
- form8-k.htm (8-K) — 36KB
- ex99-1.htm (EX-99.1) — 25KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001493152-24-043141.txt ( ) — 244KB
- cocp-20241031.xsd (EX-101.SCH) — 3KB
- cocp-20241031_lab.xml (EX-101.LAB) — 33KB
- cocp-20241031_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 31, 2024 Cocrystal Pharma, Inc. By: /s/James Martin Name: James Martin Title: Chief Financial Officer and Co-Chief Executive Officer